NANOMEDICINES FOR TARGETED CANCER TREATMENT
Arrogene’s team of scientists has developed a family of related bio-polymer based nano agents that are capable of crossing the blood-brain-barrier. Polyolefin™ is a new drug delivery system can both identify cancer cell types through “virtual biopsies,” as well as target the molecular backbone of cancer.
Polycefin™ has been shown to be a highly effective targeted delivery platform for diagnostic imaging of tumors and other conditions through Magnetic Resonance Imaging (MRI). It can be specifically targeted to different cancer cell types and can deliver either a variety of therapeutic payloads or imaging agents to the tumor. Non-toxic and biodegradable, Polycefin™ does not provoke an immune response upon administration. Promising in vivo studies show evidence that, when attached to Polycefin™, drugs for cancer therapy could have increased treatment efficacy, lower toxicity and reduced side effects.
Polycefin’s ability to pass through the blood-brain barrier, long a key obstacle to the treatment of brain tumors, makes it ideally suited for use as a diagnostic and/or therapeutic mechanism to treat cancers that result in mestastic brain tumors—such as breast and lung. With between 120,000 and 140,000 cases of secondary brain cancers diagnosed annually, the need for therapeutic and diagnostic products is great and the annual market potential is estimated to exceed $30 billion for therapeutics and $500 million for diagnostics.
How Polycefin Crosses the Blood-Brain Barrier
Nanomedicines in Development
Arrogene is developing nanomedicine products for treatment of primary brain, lung, and triple negative breast cancer (AG101) and HER2-positive breast cancer and its metastasis (AG102).
In-vivo studies of AG101 demonstrated a 10-fold brain tumor reduction and significantly increased survival in animal models. These results show how AG101 works as ground-breaking anti-cancer nano medicine agent for blood-brain-barrier penetration, and suppression of untreatable brain and other cancers.
In pre-clinical animal trials, AG102 demonstrates a 50% higher tumor reduction than competing technologies in pre-clinical studies. Also, like AG101, AG102 overcomes drug resistance and systemic toxicity.
MR Imaging Diagnostics: “Virtual Biopsy”
Our diagnostic product development effort has focused on pre-clinical work on imaging agents including Polycefin-based imaging product (AG103) for use in Magnetic Resonance Imaging (MRI). This tumor-targeting nanomedicine holds promise for challenging diagnoses, as well as providing a novel tool that can help assess disease progression in patients undergoing treatment.
In this respect, Polycefin can provide a “virtual biopsy” in cases when an ordinary biopsy is too risky for the patient. Early indications for the diagnostic imaging product line are primary lung, brain and breast cancers and their metastases into the brain. As survival rates for these primary cancers improve, an increasingly significant percentage of the patient population develops metastatic forms of these cancers, which are often diagnosed at a late stage and then have few or no treatment options.
Polycefin’s proven ability to pass through the blood-brain tumor barrier makes it ideally suited for use as a diagnostic tool for cancers affecting the central nervous system.
Glioblastoma multiforme (GBM)
GMB is the leading type of brain cancer and affects 24,000 people each year in the USA. According to the National Cancer Institute, glioblastoma is classified as “untreatable type of cancer”. Currently, there are no effective treatments for GBM, and survival rates are very low, with 15 months on average. A major challenge in treating GBM is the difficulty in getting therapeutic agents, such as drugs or biological therapies, across the blood-brain-barrier. PolycefinTM has been demonstrated to cross this barrier and deliver its therapeutic payload directly to the glioblastoma cells.
Brain metastasis from cancers such as breast and lung is a significant clinical problem. Progress in primary breast and lung cancer treatment has led to an increase in patient survival but has also increased the chance of residual tumor cells to metastasize to the brain where treatment is difficult and patient life expectancy is short. Lung and breast cancers are the top tumors associated with brain metastasis, which accounts for 20-30% of cancer deaths annually. PolycefinTM variants able to cross the blood-brain-barrier have been developed that treat not only primary breast and lung cancer, but also brain metastases.
Our team has extensively published data relating to our research in leading scientific journals. Click below for our scientific bibliography. read more here
Our products, technologies, and manufacturing processes are protected by a comprehensive patent portfolio. Our patent portfolio might strengthen or extend any commercial drug being delivered with Polycefin.
If you are interested in exploring collaboration in our imaging or therapeutics applications, please contact us.